Somewhat Positive Press Coverage Somewhat Unlikely to Impact Amedisys (AMED) Stock Price

News stories about Amedisys (NASDAQ:AMED) have trended somewhat positive on Sunday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amedisys earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the health services provider an impact score of 45.4432418952044 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

Amedisys (AMED) traded up $0.23 during mid-day trading on Friday, hitting $54.76. 337,048 shares of the company were exchanged, compared to its average volume of 320,680. The firm has a market cap of $1,858.39, a PE ratio of 43.81, a PEG ratio of 1.17 and a beta of 0.71. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.33 and a current ratio of 1.33. Amedisys has a 1-year low of $43.07 and a 1-year high of $65.91.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, November 7th. The health services provider reported $0.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.02. The company had revenue of $380.20 million during the quarter, compared to analyst estimates of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.36 EPS. analysts expect that Amedisys will post 2.24 earnings per share for the current fiscal year.

AMED has been the subject of several research reports. SunTrust Banks restated a “buy” rating and issued a $70.00 target price on shares of Amedisys in a research note on Friday, November 10th. Craig Hallum restated a “buy” rating and issued a $68.00 target price (up from $55.00) on shares of Amedisys in a research note on Thursday, November 9th. Jefferies Group restated a “buy” rating and issued a $60.00 target price on shares of Amedisys in a research note on Thursday, October 12th. Mizuho reiterated a “buy” rating and set a $65.00 price objective (up from $55.00) on shares of Amedisys in a research note on Wednesday, November 8th. Finally, Benchmark upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $56.00 price objective on the stock in a research note on Thursday, November 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. Amedisys has a consensus rating of “Hold” and a consensus price target of $61.00.

WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Amedisys (AMED) Stock Price” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/14/amedisys-amed-receives-news-impact-score-of-0-15.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply